Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | PAM | P19021 | 2/20 | 0.48 |
| ▸ | CES2 | O00748 | 4/20 | 0.48 |
| ▸ | CES1 | P23141 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | PPARD | Q03181 | 3/20 | 0.44 |
| ▸ | PPARA | Q07869 | 3/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10411539 | 0.98 | DGKA (0.52) | DGKALMNACNR2PAMCES2 | |
| SCHEMBL8393818 | 0.98 | DGKA (0.57) | DGKALMNACNR2PAMCES2 | |
| SCHEMBL8128698 | 0.98 | DGKA (0.57) | DGKALMNACNR2PAMCES2 | |
| Hydrochloric Acid SCHEMBL5779913 | 0.98 | DGKA (0.52) | DGKALMNACNR2PAMCES2 | |
| SCHEMBL5855334 | 0.98 | DGKA (0.57) | DGKALMNACNR2PAMCES2 | |
| SCHEMBL23754644 | 0.98 | DGKA (0.57) | DGKALMNACNR2PAMCES2 | |
| SCHEMBL11898443 | 0.93 | — | — | |
| Hydrochloric Acid SCHEMBL20820002 | 0.91 | CES1 (0.44) | DGKALMNACNR2PAMCES2 | |
| SCHEMBL28871068 | 0.91 | TSHR (0.50) | DGKALMNACNR2PAMMAPT | |
| SCHEMBL23909440 | 0.87 | CNR2 (0.68) | LMNACNR2MAPTPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114349800-B | Ferrocene derivative and synthetic method and application thereof | 深圳清华大学研究院 | 2023-08-15 | — | — | CN | disclosed |
| EP-4074344-A1 | TARGETING LIPIDS | Arbutus Biopharma Corporation (CA) | 2022-10-19 | — | — | EP | disclosed |
| CN-114349800-A | Ferrocene derivative and synthesis method and application thereof | 深圳清华大学研究院 | 2022-04-15 | — | — | CN | disclosed |
| US-20190099493-A1 | Targeting Lipids | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-04-04 | — | — | US | disclosed |
| CN-109553712-A | A kind of catalytic component and its catalyst for olefinic polymerization | 中国石油化工股份有限公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-109553705-A | A kind of catalytic component and preparation method thereof for olefinic polymerization | 中国石油化工股份有限公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-104876955-B | Arginase inhibitor and its treatment use | 马尔斯公司 | 2018-11-23 | — | — | CN | disclosed |
| US-9814777-B2 | Targeting lipids | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-11-14 | — | — | US | disclosed |
| EP-3156077-A1 | TARGETING LIPIDS | Arbutus Biopharma Corporation (CA) | 2017-04-19 | — | — | EP | disclosed |
| EP-2231195-B1 | TARGETING LIPIDS | ARBUTUS BIOPHARMA CORP (CA) | 2017-03-29 | — | — | EP | disclosed |
| US-20160375137-A9 | TARGETING LIPIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2016-12-29 | — | — | US | disclosed |
| US-20140179761-A1 | TARGETING LIPIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2014-06-26 | — | — | US | disclosed |
| EP-2231195-A2 | TARGETING LIPIDS | Alnylam Pharmaceuticals Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090247608-A1 | Targeting Lipids | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2009082607-A2 | TARGETING LIPIDS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | WO | disclosed |
| CN-101052656-A | New chiral columns with broad chiral selectivity | UNIV VANDERBILT (US) | 2007-10-10 | — | — | CN | disclosed |
| EP-1080368-B1 | MOLECULAR ROD AND USES | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2005-05-04 | — | — | EP | disclosed |
| EP-1080368-A1 | MOLECULAR ROD AND USES | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999061912-A1 | MOLECULAR ROD AND USES | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1999-12-02 | — | — | WO | disclosed |
| US-4873326-A | Process for the preparation of N-alkylated caprolactams | BAYER AKTIENGESELLSCHAFT (DE) | 1989-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247608-A1 | Targeting Lipids | LY96, ABHD10, APOB | DGKA 2297/4885LMNA 180/4885CNR2 1995/4885 |
| US-20140179761-A1 | TARGETING LIPIDS | LY96, ABHD10, APOB | DGKA 2280/4885LMNA 169/4885CNR2 2036/4885 |
| US-20190099493-A1 | Targeting Lipids | APOB, LY96, ABHD10 | DGKA 2237/4885LMNA 419/4885CNR2 2165/4885 |
| US-20160375137-A9 | TARGETING LIPIDS | LY96, ABHD10, APOB | DGKA 2280/4885LMNA 169/4885CNR2 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.